The effects of recombinant eel growth hormone (reGH).methyltestosterone (MT)and L-thyroxine (T4)on the growth of red sea bream. Pagrosomus major.were investigated.Administration of reGH to fry by immersion at 2 mg 1 f...The effects of recombinant eel growth hormone (reGH).methyltestosterone (MT)and L-thyroxine (T4)on the growth of red sea bream. Pagrosomus major.were investigated.Administration of reGH to fry by immersion at 2 mg 1 for 2 hevery 5 dsys resulted in significant increase in both weight and length.but the condition factor (CF) diminished relative to that of similarly treated controls over the 37day treatment period.Immersion in 0.1 mg:1 T4 also resulted in significant increase in both weight and length and higher survival rate of test fry compared to the controls. Immersion in MT had less effect on growth and high-dose resulted in high mortality.In the second study.injection of 2 μg reGH(gwk)caused a significant increase in the specific growth rate (SGR) of test red sea bream fingerlings relative to that of the controls during the 4-week treatment period and maintained the increasing trend over the post-treatment period (weeks 4-6).Injection of MT at a dosage of 1μg (gwk) resulted in a significant展开更多
Objective: To determine the incidence of deafness in patients suffering from goiterous hypothyroidism exclusively and to evaluate the role of L-thyroxine therapy in improving the hearing in this group of patients. Stu...Objective: To determine the incidence of deafness in patients suffering from goiterous hypothyroidism exclusively and to evaluate the role of L-thyroxine therapy in improving the hearing in this group of patients. Study Design: A prospective cohort study. Materials and Methods: Hearing status was evaluated in a sample size of 100 consecutive patients reporting to the ENT/Endocrinology department of Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP with the diagnosis of goitrous hypothyroidism. The study group included patients in the age group of 5 to 65 years belonging to either sex. Patients with detected hearing loss were categorized into group A, and all other patients were designated group B. L-Thyroxine treatment for goitrous hypothyroidism was initiated in all the cases. At the end of 6 months, a repeat audiogram was done in all the patients in order to evaluate the efficacy of the said treatment protocol on the hearing in these patients. The data were tabulated and statistically analysed using Paired Students “t” test. Results: An overall 39% hearing loss was observed in patients with goitrous hypothyroidism. 15% cases had sensorineural hearing loss, 13% had mixed hearing loss and 8% had a conductive hearing loss. A statistically significant hearing improvement was recorded in this study by L-thyroxine treatment in group-A, and no deterioration of hearing was recorded in group-B. Conclusions: The incidence of sensorineural hearing is less in patients with goitrous hypothyroidism (15%) as compared with the overall incidence of sensorineural hearing loss reported for hypothyroidism (30%-40%). Further, there is a definitive improvement in hearing with the use of L-thyroxine treatment of goitrous hypothyroidism.展开更多
文摘The effects of recombinant eel growth hormone (reGH).methyltestosterone (MT)and L-thyroxine (T4)on the growth of red sea bream. Pagrosomus major.were investigated.Administration of reGH to fry by immersion at 2 mg 1 for 2 hevery 5 dsys resulted in significant increase in both weight and length.but the condition factor (CF) diminished relative to that of similarly treated controls over the 37day treatment period.Immersion in 0.1 mg:1 T4 also resulted in significant increase in both weight and length and higher survival rate of test fry compared to the controls. Immersion in MT had less effect on growth and high-dose resulted in high mortality.In the second study.injection of 2 μg reGH(gwk)caused a significant increase in the specific growth rate (SGR) of test red sea bream fingerlings relative to that of the controls during the 4-week treatment period and maintained the increasing trend over the post-treatment period (weeks 4-6).Injection of MT at a dosage of 1μg (gwk) resulted in a significant
文摘Objective: To determine the incidence of deafness in patients suffering from goiterous hypothyroidism exclusively and to evaluate the role of L-thyroxine therapy in improving the hearing in this group of patients. Study Design: A prospective cohort study. Materials and Methods: Hearing status was evaluated in a sample size of 100 consecutive patients reporting to the ENT/Endocrinology department of Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP with the diagnosis of goitrous hypothyroidism. The study group included patients in the age group of 5 to 65 years belonging to either sex. Patients with detected hearing loss were categorized into group A, and all other patients were designated group B. L-Thyroxine treatment for goitrous hypothyroidism was initiated in all the cases. At the end of 6 months, a repeat audiogram was done in all the patients in order to evaluate the efficacy of the said treatment protocol on the hearing in these patients. The data were tabulated and statistically analysed using Paired Students “t” test. Results: An overall 39% hearing loss was observed in patients with goitrous hypothyroidism. 15% cases had sensorineural hearing loss, 13% had mixed hearing loss and 8% had a conductive hearing loss. A statistically significant hearing improvement was recorded in this study by L-thyroxine treatment in group-A, and no deterioration of hearing was recorded in group-B. Conclusions: The incidence of sensorineural hearing is less in patients with goitrous hypothyroidism (15%) as compared with the overall incidence of sensorineural hearing loss reported for hypothyroidism (30%-40%). Further, there is a definitive improvement in hearing with the use of L-thyroxine treatment of goitrous hypothyroidism.
